Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics (PK), and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non—small cell lung cancer. (NSCLC).

 G12C mutation and adenocarcinoma, says Govindan. More than 85% of them had more than two prior lines of therapy, making this a typical group of patients with NSCLC. However, the findings thus far have not been typical.

AMG 510 was found to be well tolerated and showed antitumor activity. The investigators hope to see similar trends regarding safety, PK, and efficacy when more data becomes available.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

IASLC World Conference on Lung Cancer

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Dr. Govindan on the Phase I Results of AMG 510 Evaluated in NSCLC